Bausch Health (BHC) Q1 2026 earnings review
Top-Line Streaks Continue, But a $1.4B Pipeline Failure Crushes GAAP Earnings
Bausch Health delivered its twelfth consecutive quarter of revenue and adjusted EBITDA growth (excluding Bausch + Lomb). Consolidated revenue grew 12% to $2.52 billion, driven by surging volume in Salix and a massive 51% jump in Solta Medical. However, the bottom line tells a painful story: GAAP Net Loss plunged to $1.43 billion. This was driven almost entirely by a $1.42 billion goodwill impairment charge related to the failed Phase 3 trials for Salix's RED-C program. While the operational cash-generation engine remains healthy, the pipeline failure highlights the pressure management faces to find new growth before Xifaxan loses exclusivity. Guidance for FY26 was reaffirmed, projecting stable 2-5% top-line growth.
🐂 Bull Case
The core commercial engine is humming. Q1 marked 12 consecutive quarters of top-line and adjusted EBITDA growth for Bausch Health (excluding B+L), proving that the existing portfolio can consistently generate cash.
Solta accelerated to 51% reported revenue growth, aided by the successful integration of the Shibo distribution business in China and strong underlying organic demand in the APAC region.
🐻 Bear Case
The RED-C program's Phase 3 failure resulted in a $1.42 billion goodwill impairment this quarter. With Xifaxan facing patent loss in 2028, failing to bring RED-C to market removes a critical replacement driver.
The company spent $402 million on interest expense in Q1 alone, eating up the vast majority of its gross operating profits and limiting capital available for crucial business development.
⚖️ Verdict: ⚪
Neutral. The commercial execution is undeniably strong, as evidenced by double-digit growth in key segments. However, the $1.4B impairment charge is a stark reminder of the pipeline risk, leaving the company heavily dependent on Xifaxan and future M&A to bridge the looming 2027/2028 patent and pricing cliffs.
Key Themes
RED-C Failure Crystalizes on the Balance Sheet
Following the disappointing news in late 2025 that the RED-C Phase 3 trials missed their primary endpoints, the financial impact has now hit the books. Bausch recorded a massive $1.42 billion goodwill impairment charge directly tied to this program. This effectively resets the Salix pipeline narrative and heightens the pressure on recent business development acquisitions, like Larsucosterol, to deliver.
Salix Continues to Carry the Load
Accelerating. The Salix segment generated $639 million in Q1, an 18% YoY increase. This was driven heavily by Xifaxan, which surged 21%. Management's strategy to maximize Xifaxan sales through AI-driven marketing and commercial execution is working flawlessly, generating the cash needed to service the company's debt.
Solta Medical Reaps the Benefits of Shibo Acquisition
Accelerating. Solta Medical was the standout segment, growing 51% YoY to $171 million. While organic growth was a very healthy 19% (led by South Korea), the remaining 32% boost came from the recent acquisition of Shibo's aesthetics business in China. By shifting from a distributor model to direct sales in China, Bausch is successfully capturing higher margins and deeper market penetration.
Diversified Segment Remains a Drag
Stable decline. The Diversified segment (Neuroscience, Dermatology, Generics, Dentistry) continues to bleed revenue, dropping 10% YoY to $185 million. Neuroscience, the largest sub-segment, fell from $118M to $113M, while Dermatology dropped from $46M to $33M. This persistent weakness dilutes the overall growth profile of the company.
The Looming Xifaxan Cliff
While Xifaxan's 21% growth is spectacular today, the macro picture remains threatening. The drug will face Medicare Part D price negotiations under the Inflation Reduction Act (IRA) taking effect in 2027, followed by a scheduled generic entry (LOE) on January 1, 2028. Every quarter of Xifaxan outperformance simultaneously increases the concentration risk for when those cliffs arrive.
Other KPIs
Up 27% from $661 million in 25Q1. This highlights that despite the heavy GAAP net losses driven by the impairment, the underlying cash-generating capability of the commercialized portfolio expanded significantly, benefiting from higher gross profits and sales volumes.
Accelerating slightly. B+L revenue grew 9% reported and 6% organically, up from the $1.14 billion posted a year ago. Bausch Health continues to hold its majority stake, stating it remains committed to evaluating options to unlock value from this asset.
Stable but extremely high. While debt maturities have been successfully pushed out to 2028 and beyond via recent refinancings, the cost to carry this debt is massive. Q1 interest expense of $402 million offset more than 15% of the company's entire top-line revenue.
Guidance
Stable. The midpoint of $10.795 billion implies a 2% to 5% YoY growth rate over FY25. This was reaffirmed from previous forecasts, showing management's confidence in near-term demand resilience despite tariff and geopolitical uncertainties.
Stable. Implies 3% to 5% YoY growth. Reaffirmed from prior guidance.
Decelerating from the current quarter. Q1 growth for this segment was 14%, but the full-year guidance suggests a much softer remainder of the year. This implies tougher comps in the back half of the year, or anticipated normalization in Xifaxan volume.
Key Questions
Business Development Strategy Post-RED-C
With the massive $1.4B impairment signaling the end of the RED-C program, how does this shift your capital allocation priorities regarding M&A? Are you accelerating the search for late-stage hepatology assets to replace Xifaxan?
Solta Margin Profile in China
Solta reported 51% growth aided by the Shibo acquisition. Can you discuss the margin impact of shifting from a distributor to a direct sales model in China, and how tariffs might affect this profitability moving forward?
Bausch + Lomb Separation Timeline
You noted you remain committed to maximizing the value of the B+L asset. Given the extended debt runway secured last year, is there a target valuation or specific market condition you are waiting for before executing a sale or spin-off?